Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
11.09
+1.63 (17.21%)
Oct 30, 2024, 4:00 PM EDT - Market closed
Surrozen Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
42
Market Cap
35.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 12.50M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
FibroGen | 173.82M |
Neuronetics | 72.07M |
DarioHealth | 19.15M |
NeuroOne Medical Technologies | 3.92M |
Onconetix | 1.46M |
Longeveron | 1.23M |
IGC Pharma | 1.06M |
SRZN News
- 5 weeks ago - Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - GlobeNewsWire
- 2 months ago - Surrozen Provides Second Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 5 months ago - Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling - GlobeNewsWire
- 5 months ago - Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan - GlobeNewsWire
- 5 months ago - Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis - GlobeNewsWire
- 6 months ago - Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting - GlobeNewsWire
- 6 months ago - Surrozen Provides First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 7 months ago - Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis - GlobeNewsWire